Project Grant R01DK148455
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $990K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $842,732 on July 8, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate pathway-specific polygenic scores that predict individual metabolic responses to weight loss interventions. The award funds research testing whether pathway-specific polygenic scores (PPGSs) can identify biological pathways that modify how...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $156,510 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on July 1, 2026. The project, "Precision Metabolic Risk Stratification in Depression Via Multi-Omics and EHR," addresses the elevated type 2 diabetes risk in individuals with major depressive disorder, particularly those treated with selective...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $123,750 on May 18, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop molecularly-informed polygenic scores predicting individual response to omega-3 fatty acid supplementation. The project will generate interaction-focused polygenic scores quantifying differences in omega-3 fatty acid...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $835,245 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to evaluate evidence-based strategies for preventing weight regain after discontinuation of high-dose glucagon-like peptide-1 (GLP-1) agonist therapy in adults with obesity history but...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $158,960 on September 30, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct genetic research on taste preferences and their relationship to metabolic disease risk and GLP-1 receptor agonist response. The research will perform genome-wide association studies of five taste preferences, apply Mendelian randomization and polygenic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Broad Institute, Inc. $1,647,485 on September 19, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct massive-scale genomic risk assessment across monogenic and common forms of diabetes. The award will support analysis of the largest dataset of rare variation linked to diabetes phenotyping, comprising more than 1.1 million participants (33 percent...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Emory University $824,296 on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify novel type 2 diabetes phenotypes and assess their association with diabetes complications through longitudinal analysis of clinical data and polygenic risk scores. The research leverages the Kaiser Permanente Research Bank cohort, a nationally representative dataset...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation $561,565 on July 30, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a Project Grant (R01DK145514) investigating the molecular mechanisms by which testican-2 protects against chronic kidney disease. The award funds research establishing the protective effect of circulating testican-2 in clinically relevant kidney disease...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $123,750 to Massachusetts General Hospital on February 4, 2026, for development of an audio-based digital intervention to improve diabetes medication adherence among Latino adults with low health literacy. The recipient, The General Hospital Corporation (doing business as Massachusetts General Hospital), will develop AudibleDiabetesRx, an audio-based tool delivering on-demand, Spanish-language medication information...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham & Women's Hospital Inc. $899,135 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a prospective study characterizing the serological microbial-viral interactome and gut microbiome-virome in type 2 diabetes development. The research uses phage immunoprecipitation sequencing (PHIP-SEQ) to profile antibody responses to a large antigen...